Anne Prener, an experienced haematology executive, has been appointed chief executive officer of Freeline Therapeutics Ltd, which is developing a gene therapy for bleeding disorders. Dr Prener was previously CEO of Gyroscope Therapeutics Ltd, another gene therapy start-up. Both Freeline and Gyroscope are majority owned by the Syncona investment group. Dr Prener has served as head of haematology at Baxalta, which is now part of Shire Plc, and also as senior vice president for haemophilia research and development at Novo Nordisk A/S. She holds an MD as well as a PhD in epidemiology from Copenhagen University in Denmark.
Freeline Therapeutics announced the appointment on 10 July 2017.
Copyright 2017 Evernow Publishing Ltd